Keensight Capital is one of the leading private equity managers dedicated to pan-European Growth Buyout investments.
Keensight Capital are investing behind CatSci management to support continued growth of the core business via capability and site expansion, as well as the development of GMP capabilities and the expansion of its offering in oligonucleotide services. Keensight Capital will bring its expertise and successful track record of investments in the CRDMO (Contract Development and Manufacturing Organisation) space, with the ability to help accelerate growth through accretive M&A. This will enable CatSci to continue offering “more and better” to its customers in order to deliver best-in-class medicines for patients worldwide.
We were advised by corporate finance advisory firm, Shaw & Co, throughout the investment process.
Read more here.